| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
human Caspase-3 1.7 μM (IC50)
MMPSI targets matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases. MMPs are involved in the degradation of extracellular matrix components and play critical roles in cell migration, tissue remodeling, and angiogenesis. By inhibiting MMP activity, MMPSI modulates extracellular matrix degradation and cell migration. The compound's selectivity for specific MMP isoforms influences its biological effects and potential therapeutic applications. |
|---|---|
| ln Vitro |
In cell-free biochemical assays, MMPSI inhibits the enzymatic activity of matrix metalloproteinases. The compound's inhibition of MMPs can be assessed using fluorogenic substrates that are cleaved by MMPs. The IC50 is determined from dose-response curves. The compound's selectivity for different MMP isoforms can be assessed by testing against a panel of purified MMP enzymes.
|
| ln Vivo |
In cell-based assays, MMPSI inhibits MMP activity, leading to reduced extracellular matrix degradation and cell migration. The compound's effects are evaluated in cell lines by measuring cell invasion, migration, and matrix degradation. Inhibition of MMPs can also affect cell proliferation, angiogenesis, and other cellular processes. The compound can be used to study the role of MMPs in various diseases.
|
| Enzyme Assay |
The cell-free assay for MMP inhibition involves measuring the enzymatic activity of purified MMP enzymes in the presence of the compound. The assay uses a fluorogenic peptide substrate that is cleaved by MMPs, releasing a fluorescent signal. The compound is incubated with the enzyme and substrate, and the fluorescence is measured over time. The IC50 is determined from dose-response curves. The compound's selectivity is assessed by testing against a panel of MMP isoforms.
|
| Cell Assay |
Cell-based assays for MMPSI involve culturing cancer cell lines or other relevant cells and treating them with the compound at concentrations ranging from 0.1 to 100 μM. Cell invasion and migration are assessed using transwell or scratch assays. Matrix degradation is assessed by measuring the degradation of labeled extracellular matrix components. Cell proliferation is assessed using MTT or CCK-8 assays. The compound's effects on MMP activity and downstream signaling are assessed by Western blotting.
|
| Animal Protocol |
In animal models, MMPSI has been evaluated for its ability to inhibit MMP activity and reduce disease progression in models of cancer, arthritis, and cardiovascular diseases. Typical studies involve administration of the compound to mice via oral, intraperitoneal, or intravenous routes. Disease progression, tumor growth, and tissue remodeling are assessed. MMP activity in tissues is measured using zymography or other assays.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MMPSI have not been extensively reported. As a small molecule MMP inhibitor, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound's pharmacokinetic properties depend on its specific chemical structure. Further pharmacokinetic studies would be required to determine plasma half-life, clearance, and metabolic pathways.
|
| Toxicity/Toxicokinetics |
MMPSI is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent. As an MMP inhibitor, the compound may have effects on normal tissue remodeling processes. Standard toxicity studies in rodents would be required to determine the maximum tolerated dose and safety profile.
|
| References | |
| Additional Infomation |
MMPSI is a research-grade compound supplied for MMP inhibition studies. It is not an approved pharmaceutical and has no clinical trial history. The compound is a matrix metalloproteinase inhibitor that can be used to study the role of MMPs in cancer, arthritis, and other diseases. This product is intended for research use only.
|
| Molecular Formula |
C14H16N2O5S
|
|---|---|
| Molecular Weight |
324.35
|
| Exact Mass |
324.078
|
| CAS # |
220509-74-0
|
| PubChem CID |
9840223
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.777
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
570
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC[C@@H]1CCCN1S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
|
| InChi Key |
SLQMNVJNDYLJSF-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C14H16N2O5S/c1-21-8-9-3-2-6-16(9)22(19,20)10-4-5-12-11(7-10)13(17)14(18)15-12/h4-5,7,9H,2-3,6,8H2,1H3,(H,15,17,18)/t9-/m0/s1
|
| Chemical Name |
5-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl-1H-indole-2,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~308.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0831 mL | 15.4154 mL | 30.8309 mL | |
| 5 mM | 0.6166 mL | 3.0831 mL | 6.1662 mL | |
| 10 mM | 0.3083 mL | 1.5415 mL | 3.0831 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
